This session will provide an overview of an ongoing DIA study on enhancing the integration of patient experience data to understand Tolerability in immune-oncology clinical trials.
Learning Objectives
Understand the significance of advancing patient-centric tolerability measurement in immune-oncology trials to enhance patient outcomes; Gain insights into ongoing the study and future steps aimed at addressing the real-world needs of patients through a multistakeholder framework.
